Literature DB >> 18434935

Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.

Michael E Speer1, Caraciolo J Fernandes, Marnie Boron, Jessie R Groothuis.   

Abstract

The Palivizumab Outcomes Registry collected data on 19,548 high-risk infants who received > or =1 dose of palivizumab and followed prospectively from 2000 through 2004. Ninety-one children with cystic fibrosis (CF) were identified who received palivizumab off label. None of the infants with CF who received prophylaxis was hospitalized as a result of respiratory syncytial virus lower respiratory tract infection. Evaluations of palivizumab use in infants with CF could be warranted.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18434935     DOI： 10.1097/INF.0b013e3181673c15

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  13 in total

Review 1.  Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Authors:  Karen A Robinson; Olaide A Odelola; Ian J Saldanha
Journal:  Cochrane Database Syst Rev       Date:  2016-07-20

2.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

3.  Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis.

Authors:  Mukta Jain; Anne H Thomson
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

4.  Respiratory Syncytial Virus Prophylaxis in Special Populations: Is it Something Worth Considering in Cystic Fibrosis and Immunosuppression?

Authors:  William A Prescott; David J Hutchinson
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

5.  Respiratory syncytial virus: diagnosis, treatment and prevention.

Authors:  Lea S Eiland
Journal:  J Pediatr Pharmacol Ther       Date:  2009-04

6.  The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model.

Authors:  Ashleigh A McGirr; Kevin L Schwartz; Upton Allen; Melinda Solomon; Beate Sander
Journal:  Hum Vaccin Immunother       Date:  2016-10-21       Impact factor: 3.452

7.  Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Authors:  Drucy Borowitz; Karen A Robinson; Margaret Rosenfeld; Stephanie D Davis; Kathryn A Sabadosa; Stephanie L Spear; Suzanne H Michel; Richard B Parad; Terry B White; Philip M Farrell; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

Review 8.  Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.

Authors:  Helena Edlund; Johanna Melin; Zinnia P Parra-Guillen; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 5.577

9.  Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.

Authors:  B Paes; I Mitchell; A Li; K L Lanctôt
Journal:  Eur J Pediatr       Date:  2011-12-28       Impact factor: 3.183

Review 10.  Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective.

Authors:  Nusrat Homaira; William Rawlinson; Thomas L Snelling; Adam Jaffe
Journal:  Int J Pediatr       Date:  2014-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.